Groundbreaking innovation
Boasting a wealth of expertise in oncology, Minomic is making waves globally collaborating with universities, research institutes and companies.
Minomic
Our flagship product, MiCheck® Prostate, is an advanced algorithm that combines the results of three serum immunoassays with relevant clinical factors that accurately indicate the likelihood of aggressive prostate cancer.
Minomic is dedicated to developing MiCheck® Prostate as a supplement to other clinical factors and test results.
Rather than replacing the judgment and experience of urologists, MiCheck® Prostate aims to assist physicians in making informed decisions about whether a prostate biopsy is necessary for male patients under consideration.